#IPI2024

Prof. Dominic   Hegarty

Consultant in Pain Management and Neuromodulation, Mater Private Hospital Cork, Ireland.
Senior Clinical Lecturer UCC & ASSERT, Ireland.
Honorary Consultant, Guy’s & St. Thomas’ Hospital, London, England.
Clinical Lead Neuromodulation Research, Tyndall National Institute, Ireland.
President Elect World Institute of Pain (WIP)
He is a Consultant in Pain Management & Neuromodulation at the Mater Private Hospital, Cork, Senior Clinical Lecturer and faculty member of ASSERT training at University College Cork where he promotes educational training in pain medicine.
At present he is the incoming President Elect of World Institute of Pain (WIP), Immediate past Honorary treasurer of WIP and on the Advisory Board of PainCast. In 2017 Dr. Hegarty hosted the WIP World congress in Dublin. He has gone on to be Clinical Lead of Neuromodulation Research, at Tyndall National Institute, UCC and has developed new device design Dr. Hegarty is a faculty member on several international organization including WIP, IASP and ERSA. He is an active researcher & has published extensively on pain management. He is an examiner on the FIPP fellowship exams. As a fellow at Guy’s & St.
Thomas’ Hospital, London he developed his skills in neuromodulation and is presently an Honorary Consultant there. Dr. Hegarty is the Clinical Director of Pain Relief Ireland (www.painreliefireland.ie) and the senior medial advisor to a number of med-tech companies who believes in providing multidisciplinary and interventional options for his patients in a timely fashion. He truly believes that neuromodulation offers great potential therapy options for certain individuals and we need to develop patient pathways to identify and manage these individuals.
Relevant disclosures
Dr. Hegarty has active research interests in several pain related areas. He is a clinical advisor to Capri Medical, Platform 14 and Senior Medical Advisor with Platform14. He has received honorium and unrestricted educational grants form Medtronic, Boston Scientific, Pfizers, and Grunenthal in this area. Dr. Hegarty will not be speak directly on the use of any specific products.